Penumbrainc Inc.

About Penumbrainc Inc.

Penumbrainc is a biotherapeutics company advancing precision-engineered antibodies that modulate the complement system to treat severe autoimmune and inflammatory diseases. Its lead programs target dysregulated complement activation underlying conditions such as paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, and Guillain-Barré syndrome. The company applies structural biology insights to create long-acting, subcutaneous therapies with improved safety and dosing convenience over existing intravenous treatments. Founded in 2020 and headquartered in South San Francisco, Penumbrainc is advancing candidates through preclinical and early clinical development with the goal of delivering first-in-class complement inhibitors to patients with high unmet medical need.